Interested in the cost-effectiveness of cetuximab vs bevacizumab in the 1L treatment of RAS wild-type metastatic colorectal cancer in Germany?  Together with LM University Hospital Munich and Merck,  Ingress-health has presented the cost-effectiveness results at ASCO GI  2018  (Board L23) in San Francisco, USA.

The poster will be soon available for download from our website!